Latest It Compliance News

The ASX has suspended the securities of over 20 companies for failing to lodge their periodic reports on time, signaling regulatory vigilance and raising questions about compliance and market impact.

Pure Hydrogen Corporation reported FY2025 revenue growth alongside a significant non-cash impairment charge, while progressing its clean hydrogen vehicle technologies and planning a spinout of its Australian gas assets.

Memphasys Limited has revised its FY25 financials to reflect a $1.12 million liability linked to uncertain compliance with R&D tax incentive rules, pending a private tax ruling.

PARKD Limited has completed the first tranche of its $0.78 million placement, issuing over 20 million shares at 3 cents each, while launching a Share Purchase Plan for existing shareholders.

Delorean Corporation has released its audited 2025 Annual Report, revealing key adjustments from its preliminary results including lower revenue, increased tax expenses, and a significant reclassification of borrowings.

Australian Pacific Coal Limited has delayed its full year accounts due to missing financial data from its Dartbrook mine subsidiary, leading to a trading suspension from October 1.

Lord Resources has completed a $814,000 placement by issuing 22 million shares, reinforcing its funding position as it advances exploration at the Ilgarari Copper Project in Western Australia.

Avada Group Limited has updated its FY25 financial results, reducing its loss after tax by $2.04 million due to tax benefit adjustments and reclassification of borrowings, while confirming no impact on operating revenue or cash flow.

FirstWave Cloud Technology has locked in a $2.5 million loan facility to accelerate its AI growth strategy and repay existing debt, complementing a recent $2.85 million equity raise.

Myer Holdings has clarified that its FY2025 earnings aligned with market forecasts, addressing concerns following a sharp share price drop after its results announcement.

EMU NL’s securities have been suspended from ASX trading due to a failure to maintain the minimum number of directors required by law. The suspension highlights governance challenges and raises questions about the company’s path to compliance.

Invex Therapeutics reveals the collapse of confidential acquisition negotiations following shareholder unrest and potential board changes, clarifying recent unusual trading activity.